A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia, in Relapse - Recurrent Adult Acute Myeloid Leukemia
Conditions: official terms
Leukemia - Leukemia, Myeloid - Leukemia, Myeloid, Acute
Conditions: Keywords
Refractory acute myeloid leukemia, Relapsed acute myeloid leukemia
Study Type
Study Phase
Phase 1/Phase 2
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Name: GO-203-2c
Type: Drug
Overall Status
This research study is studying a targeted therapy known as GO-203-2C as a possible treatment for with acute myeloid leukemia (AML) . This therapy targets cancer cells, while leaving healthy cells unaffected.This is a Phase I/II clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies.
Detailed Description
- Phase I

- The maximum tolerated dose (MTD) will be determined in the phase I section of the trial.

- Patients who fulfill eligibility criteria will be entered into the trial to GO-203-2c.

- After the screening procedures confirm participation in the research study. The investigators are looking for the highest dose of the combination of study drugs that can be administered safely without severe or unmanageable side effects in participants that have acute myeloid leukemia (AML) not everyone who participates in this research study will receive the same dose of the study drug. The dose given will depend on the number of participants who have been enrolled in the study prior and how well the dose was tolerated.

- Phase II

- A subsequent phase II section will be treated at the MTD with a goal of determining if therapy with GO-203-2c therapy results in at least a 20% response rate.

- Primary Outcome for the Phase II ---To determine if therapy GO-203-2c results in at least 20% of patients achieving a clinical response (blast response, minor response, partial response, or complete response)
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- To be considered eligible for enrollment into this study, all of the following inclusion criteria must be met during the screening period:

- Documented AML by peripheral blood and bone marrow analyses meeting WHO criteria, excluding patients with acute promyelocytic leukemia (APL)

- Patients with AML refractory to primary induction chemotherapy, relapsed disease, or age ≥ 60 and not appropriate for standard cytotoxic therapy due to age, performance status, and/or adverse risk factors according to the treating physician

- Age ≥ 18 years

- Karnofsky performance status ≥ 50% or ECOG performance status 0-2

- Life expectancy ≥ 6 weeks

- Able to understand the investigational nature of this study and to provide written consent to participate in it

- Signed written IRB-approved Informed Consent document

- Adequate hepatic and renal function:

- serum bilirubin ≤ 1.5 X institutional ULN

- serum ALT, AST, and alkaline phosphatase ≤ 2.5 X institutional ULN

- serum creatinine ≤ 2.0 mg/dL

- Negative pregnancy test in women of child-bearing potential

- Women and men of child-producing potential must agree to use effective contraceptive methods during the study period (including post-treatment observation period)

Exclusion Criteria:

- A patient will be considered not eligible for enrollment into this study if any of the following criteria are met during the screening period:

- Evidence of leukemic meningitis or other CNS involvement by leukemia

- Uncontrolled or poorly controlled hypertension (systolic BP ≥ 160 mmHg or diastolic BP ≥ 100 mmHg) Note: an isolated reading that is not sustained will be permitted.

- Evidence of NYHA Class III or IV cardiac disease, or presence of unstable life-threatening arrhythmia, or history of myocardial infarction during the past 6 months

- Active bacterial, fungal, or viral infection requiring systemic treatment

- Known infection with HIV

- History or major surgery within 4 weeks before the first dose of study treatment, or not recovered from prior surgery

- Exposure to any other investigational agent at any time within 4 weeks before the first dose of study treatment

- Exposure to any other anti-leukemic therapy (except hydroxyurea, see Section 5.5.1) within 2 weeks before the first dose of study treatment

- Pregnant or lactating female

- Unwilling or unable to comply with the requirements of the study protocol
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
Status: Recruiting
Contact: David Avigan, MD - 617-667-9920 - davigan@bidmc.harvard.edu
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Status: Not yet recruiting
Contact: Richard M. Stone, MD - 617-632-2214 - rstone@partners.org
Start Date
September 2014
Completion Date
July 2021
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page